Natural History of Multiple Human Papillomavirus Infections in Female Adolescents With Prolonged Follow-up

Weaver, Bree; Shew, Marcia L.; Qadadri, Brahim; Tu, Wanzhu; Tong, Yan; Denski, Cheryl; Fortenberry, J. Dennis; Brown, Darron R.

doi:10.1016/j.jadohealth.2010.08.003

Cited by 21 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cohort used for selecting matched cases was recruited from the longitudinal study that assessed risk and protective factors for sexually transmitted infections, known as the Young Women’s Project (YWP)[8, 11]. Recruitment for the YWP began in the fall 1999 and ended in July 2005.…”

Section: 0 Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Reduction of HPV infections through vaccination among at-risk urban adolescents

Cummings

Zimet

Brown

et al. 2012

Vaccine

Self Cite

View full text Add to dashboard Cite

Section: 0 Methodsmentioning

confidence: 99%

“…High rates of sexually transmitted infections (STIs), including HPV, and documented sexual behaviors have been reported in a longitudinally followed cohort of urban adolescent women recruited from 1999 to 2005 [8–11]. This cohort was recruited prior to HPV vaccine availability.…”

Section: 0 Introductionmentioning

confidence: 99%

Reduction of HPV infections through vaccination among at-risk urban adolescents

Cummings

Zimet

Brown

et al. 2012

Vaccine

Self Cite

View full text Add to dashboard Cite

“…Two prophylactic vaccines (Gardasil and Cervarix) developed by Merck and GSK respectively have been implemented in young adolescents [8,9]. These two vaccines, however, have shown no therapeutic effects against pre-existing infections [10].…”

Section: Introductionmentioning

confidence: 99%

Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits

Budgeon

Balogh

et al. 2014

Trials in Vaccinology

View full text Add to dashboard Cite

Long peptide immunization is a promising strategy to clear established tumors. In the current study, we investigated the therapeutic effect of a naturally existing long peptide that contained two HLA-A2.1 restricted epitopes (CRPVE1/149-157 and CRPVE1/161-169) from cottontail rabbit papillomavirus (CRPV) E1 using our CRPV/HLA-A2.1 transgenic rabbit model. A universal Tetanus Toxin helper motif (TT helper) was tagged at either the N-terminus or the carboxyl-terminus of this long peptide and designated as TT-E1 peptide and E1 peptide-TT respectively. Four groups of HLA-A2.1 transgenic rabbits were infected with wild type CRPV DNA. Three weeks post-infection, the rabbits were immunized four times with TT-E1 peptide, E1peptide only, E1 peptide -TT or TT-control peptide with two-week intervals between immunizations. Tumor outgrowth was monitored and recorded weekly. After the third booster immunization, tumors on two of the four E1 peptide-TT immunized rabbits began to shrink. One animal from this group was free of tumors at the termination of the study. The mean papilloma size of E1 peptide-TT immunized rabbits was significantly smaller when compared with that of the three other groups (P<0.05, one way ANOVA analysis). It is interesting that E1 peptide-TT vaccination not only stimulated stronger T cell mediate immune responses but also stronger antibody generations. We conclude that the location of a TT helper motif tagged at the long peptide vaccine is critical for the outcome of therapeutic responses to persistent tumors in our HLA-A2.1 transgenic rabbit model.

show abstract

“…Our finding that 11.6% of sexually inexperienced females were positive for at least 1 HPV type is consistent with findings of previous studies that enrolled females who were likely to have had sexual contact. 4-6 We found that 4.3% of sexually inexperienced females were already infected with vaccine-type HPV, potentially through hand-genital or genital, skin-to-skin contact. This demonstrates that sexually inexperienced females are at risk for HPV infection and supports national recommendations to target HPV vaccination to 11- to 12-year-old girls.…”

Section: Commentmentioning

confidence: 86%